Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Lung cancer biopsies are still being done blind more often than you’d think, leading to costly diagnostic errors.
In this episode, Reza Khorasaninejad, Founder & CEO at LEADOPTIK, discusses how advances in photonics and metasurface engineering are enabling highly miniaturized imaging systems for minimally invasive procedures. These innovations aim to address a major challenge in lung cancer biopsies: a lack of imaging guidance that can lead to significant diagnostic errors. Early clinical pilots across multiple sites are demonstrating strong performance, with one hospital already converting into a paying customer. Looking ahead, the company is partnering with Stanford Medicine to develop AI-driven decision support tools to further improve diagnostic accuracy.
Tune in to learn how next-generation imaging and AI are changing that reality and helping physicians hit the right target the first time!
Resources:
Connect with and follow Reza Khorasaninejad on LinkedIn.Follow LEADOPTIK on LinkedIn and explore their website!
